Corporate PresentationMerger 8-K Business Overview2025 Key Opinion Leader and Investor DayCorporate VideoPipeline $2.10 NASDAQ: IBRX 0 (0.00%) Minimum 15 minutes delayed. Source: LSEG Press Releases ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Gu...
“We are excited to join forces with ImmunityBio, a company and team we have collaborated with for many years across our platforms,” said Rich Adcock, NantKwest Chief Executive Officer. “With the integration of ImmunityBio’s pipeline, cutting-edge R&D capabilities, talented...
ImmunityBio’s second-generation hAd5 viral-vector vaccine is unique in targeting both S and N SARS-CoV-2 proteins to generate B and T cell memory to these antigens and, potentially, long-term immunity to the virus. In addition, the platform was...